Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer
Advanced ovarian cancer is a malignancy that spreads beyond the ovaries to the pelvis, abdomen, lungs, or lymph nodes. Effective treatment options are available to improve survival rates in patients with advanced ovarian cancer. These include radiation, surgery, chemotherapy, immunotherapy, and tar...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2024-03-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/9757 |
| _version_ | 1827317503203737600 |
|---|---|
| author | Lama Abujamous Abderrezzaq Soltani Hamda Al-Thawadi Abdelali Agouni |
| author_facet | Lama Abujamous Abderrezzaq Soltani Hamda Al-Thawadi Abdelali Agouni |
| author_sort | Lama Abujamous |
| collection | DOAJ |
| description |
Advanced ovarian cancer is a malignancy that spreads beyond the ovaries to the pelvis, abdomen, lungs, or lymph nodes. Effective treatment options are available to improve survival rates in patients with advanced ovarian cancer. These include radiation, surgery, chemotherapy, immunotherapy, and targeted therapy. Drug resistance, however, remains a significant challenge in pharmacotherapeutic interventions, leading to reduced efficacy and unfavorable patient outcomes. Combination therapy, which involves using multiple drugs with different mechanisms of action at their optimal dose, is a promising approach to circumvent this challenge and it involves using multiple drugs with different mechanisms of action at their optimal dose. In recent years, nanotechnology has emerged as a valuable alternative for enhancing drug delivery precision and minimize toxicity. Nanoparticles can deliver drugs to specific cancer cells, resulting in higher drug concentrations at the tumor site, and reducing overall drug toxicity. Nanotechnology-based drug delivery systems have the potential to improve the therapeutic effects of anti-cancer drugs, reduce drug resistance, and improve outcomes for patients with advanced ovarian cancer. This literature review aims to examine the current understanding of combining poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy in treating advanced ovarian cancer and the potential impact of nanotechnology on drug delivery.
|
| first_indexed | 2024-04-24T23:39:56Z |
| format | Article |
| id | doaj.art-40a42c8b823b4589b8dc6f2a23d8e4c9 |
| institution | Directory Open Access Journal |
| issn | 2831-0896 2831-090X |
| language | English |
| last_indexed | 2024-04-24T23:39:56Z |
| publishDate | 2024-03-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj.art-40a42c8b823b4589b8dc6f2a23d8e4c92024-03-15T13:21:04ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2024-03-0124210.17305/bb.2023.9757Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancerLama Abujamous0Abderrezzaq Soltani1Hamda Al-Thawadi2Abdelali Agouni3Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar; Office of Vice President for Research and Graduate Studies, Qatar University, Doha, QatarOffice of Vice President for Medical and Health Sciences, Qatar University, Doha, Qatar; Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, QatarDepartment of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, QatarOffice of Vice President for Research and Graduate Studies, Qatar University, Doha, Qatar; Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, Qatar Advanced ovarian cancer is a malignancy that spreads beyond the ovaries to the pelvis, abdomen, lungs, or lymph nodes. Effective treatment options are available to improve survival rates in patients with advanced ovarian cancer. These include radiation, surgery, chemotherapy, immunotherapy, and targeted therapy. Drug resistance, however, remains a significant challenge in pharmacotherapeutic interventions, leading to reduced efficacy and unfavorable patient outcomes. Combination therapy, which involves using multiple drugs with different mechanisms of action at their optimal dose, is a promising approach to circumvent this challenge and it involves using multiple drugs with different mechanisms of action at their optimal dose. In recent years, nanotechnology has emerged as a valuable alternative for enhancing drug delivery precision and minimize toxicity. Nanoparticles can deliver drugs to specific cancer cells, resulting in higher drug concentrations at the tumor site, and reducing overall drug toxicity. Nanotechnology-based drug delivery systems have the potential to improve the therapeutic effects of anti-cancer drugs, reduce drug resistance, and improve outcomes for patients with advanced ovarian cancer. This literature review aims to examine the current understanding of combining poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy in treating advanced ovarian cancer and the potential impact of nanotechnology on drug delivery. https://www.bjbms.org/ojs/index.php/bjbms/article/view/9757Ovarian carcinomascombination therapyPARP inhibitorsimmune checkpoint inhibitorsnanomedicine |
| spellingShingle | Lama Abujamous Abderrezzaq Soltani Hamda Al-Thawadi Abdelali Agouni Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer Biomolecules & Biomedicine Ovarian carcinomas combination therapy PARP inhibitors immune checkpoint inhibitors nanomedicine |
| title | Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer |
| title_full | Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer |
| title_fullStr | Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer |
| title_full_unstemmed | Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer |
| title_short | Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer |
| title_sort | advances in nanotechnology enabled drug delivery for combining parp inhibitors and immunotherapy in advanced ovarian cancer |
| topic | Ovarian carcinomas combination therapy PARP inhibitors immune checkpoint inhibitors nanomedicine |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/9757 |
| work_keys_str_mv | AT lamaabujamous advancesinnanotechnologyenableddrugdeliveryforcombiningparpinhibitorsandimmunotherapyinadvancedovariancancer AT abderrezzaqsoltani advancesinnanotechnologyenableddrugdeliveryforcombiningparpinhibitorsandimmunotherapyinadvancedovariancancer AT hamdaalthawadi advancesinnanotechnologyenableddrugdeliveryforcombiningparpinhibitorsandimmunotherapyinadvancedovariancancer AT abdelaliagouni advancesinnanotechnologyenableddrugdeliveryforcombiningparpinhibitorsandimmunotherapyinadvancedovariancancer |